Ironwood Pharmaceuticals IRWD Business Segments
| Q1 '26 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | ||
|---|---|---|---|---|---|---|
| Revenue by Product | ||||||
| Collaborative Arrangement Development And Commercialization Agreements | $200K-60.0% | $200K-68.4% | -$2.68M-547% | $500K-29.7% | $298K-70.2% | |
| Royalty | $800K0.0% | $900K+12.5% | $900K+12.5% | $800K+14.3% | —— |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- How does Ironwood Pharmaceuticals break its business down?
- Ironwood Pharmaceuticals (IRWD) reports revenue by product across 2 parts — Collaborative Arrangement Development And Commercialization Agreements and Royalty. Each is extracted from the segment footnotes and tracked over time.
- Where does Ironwood Pharmaceuticals's segment data come from?
- Segment breakdowns are pulled from the segment footnotes in Ironwood Pharmaceuticals's SEC filings (the XBRL dimensional tags), so every line ties back to a reported figure. Switch between quarterly, annual, and TTM, or open any segment for its full history.
